Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Gemcitabine in Advanced Solid Tumors or Lymphoma
NCT02414724Phase 1Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- May 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in solid tumor and lymphoma, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 21 days and Recommended Phase II Dose at 21 days. Started May 2015; status: terminated.
02
Drugs
ribociclib
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02414724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02414724.